SelectScience
Join Free
Accelerating Science
NewsDrug discovery > Lead Discovery

Cobra Biologics joins consortium to rapidly develop a COVID-19 vaccine

Cobra Biologics
30 Mar 2020
Edward Carter
Publishing / Media

Industry news

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, has announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19 (ChAdOx1), for fast-tracked clinical trials for COVID-19. ChAdOx1, is one of five frontrunner vaccines in development around the world, and expected to be the UK’s first COVID-19 vaccine. The ChAdOx1 consortium includes the University of Oxford Jenner Institute, University of Oxford Clinical Biomanufacturing Facility, the Vaccines Manufacturing and Innovation Centre (VMIC), Advent Srl, Pall Life Sciences, Cobra Biologics and Halix BV.

The ChAdOx1 consortium is currently recruiting individuals from a range of ages in the UK to trial the vaccine’s efficacy, in April 2020 – a crucial step in the vaccine’s development. Cobra is actively planning for a fast set-up phase to facilitate the efficient production of a GMP working cell bank and then 200L GMP viral vaccine. The consortium partners expect to develop and manufacture the vaccine candidate in multiple batches, to support a 1million dose scale batch size, by summer 2020.

Developed at the Jenner Institute, ChAdOx1 is one of the most promising vaccine technologies for COVID-19 as it can generate a strong immune response from one dose. The vaccine candidate allows it to be given safely to vulnerable members of the public, including children, the elderly and those with a pre-existing condition, such as diabetes.

Peter Coleman, Chief Executive at Cobra Biologics, said: “The organisations within the consortium led by the Jenner Institute are experts from across industry and academia, with the experience, capability and conviction to deliver a successful outcome. Cobra is privileged to have been invited to participate and contribute to the fight against COVID-19, as this virus continues to impact the globe exponentially.”

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Cobra BiologicsCompany website

Tags

Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Vaccine DevelopmentVaccine development focuses on creating immunizations to protect against infectious diseases. The process involves identifying antigens, developing and testing vaccine efficacy, and ensuring safety through preclinical testing and multiple clinical trial phases. Scientists use various approaches, including weakened or inactivated viruses, protein subunits, or mRNA. Advanced platforms and rapid diagnostic tools aid in vaccine research and testing. Explore vaccine development solutions in our peer-reviewed product directory; compare products, read reviews, and get pricing directly from manufacturers. CoronavirusCoronaviruses are a large family of viruses that can cause illnesses ranging from the common cold to more severe diseases like COVID-19. Research into the biology, transmission, and treatment of coronaviruses has become a global priority, particularly since the emergence of SARS-CoV-2. Understanding the virus�s structure and behavior is essential for developing vaccines, diagnostics, and antiviral treatments. Explore our peer-reviewed product directory to discover the latest research tools, diagnostic tests, vaccines, and treatments for coronavirus, compare products, read reviews, and receive pricing directly from manufacturers.

Related articles

Cobra Biologics joins consortium to rapidly develop a COVID-19 vaccine